The Role of Endoscopic Intra-Gastric Botulinum Toxin-A for Obesity Treatment.
Hadya ElshakhKhalid El-EjjiKhalid Mohsin Al-EjjiPublished in: Obesity surgery (2018)
Obesity prevalence has been increasing with devastating health and economic consequences. Botulinum toxin type A (BTX-A), a neurotoxin, is used clinically for conditions characterized by prolonged muscular contraction. Its inhibitory effects on gastric smooth muscles, in theory, make it a potential agent for obesity treatment through delayed gastric emptying and increased satiety. This review aims to examine the evidence for the use of endoscopic BTX-A injection for treating obesity. The literature search identified 60 articles with 11 primary studies as relevant for the scope of the review. Several studies have been conducted to examine the effect of BTX-A injections on obesity, including both animal and human studies. Current evidence from identified studies does not demonstrate sustained weight loss through the use of endoscopic BTX-A injection.
Keyphrases
- weight loss
- botulinum toxin
- insulin resistance
- ultrasound guided
- metabolic syndrome
- bariatric surgery
- type diabetes
- high fat diet induced
- weight gain
- roux en y gastric bypass
- healthcare
- gastric bypass
- systematic review
- case control
- endothelial cells
- adipose tissue
- risk factors
- public health
- body mass index
- mental health
- physical activity
- health information
- resistance training
- risk assessment
- obese patients
- high intensity
- human health